ZD-9379 is an antagonist of the N-methyl-D-aspartate receptor. It possesses neuroprotective properties and could potentially be used for the treatment of certain strokes.
Mechanism of action
ZD-9379 works by antagonizing (blocking) the glycine site on the NMDA receptor,[1][2] because both glycine (co-agonist) and an agonist at the main site are needed to activate the NMDA receptor, blocking the glycine binding site prevents the receptor from activating.
Potential use
In rats, ZD-9379 has been tested to help spreading depression and brain infarction, results have shown that treatment with ZD-9379 reduced the amount of spreading depressions and the volume of infarcts.[3] Another study was also able to produce similar results.[4]
References
- ^ "ZD 9379 | CAS 170142-20-8 | ZD9379 | Tocris Bioscience".
- ^ Danysz, Wojciech; Parsons, Chris G. (March 2002). "Neuroprotective potential of ionotropic glutamate receptor antagonists". Neurotoxicity Research. 4 (2): 119–126. doi:10.1080/10298420290015872. ISSN 1476-3524. PMID 12829411.
- ^ Tatlisumak, T.; Takano, K.; Meiler, M. R.; Fisher, M. (2000). "A Glycine Site Antagonist ZD9379 Reduces Number of Spreading Depressions and Infarct Size in Rats with Permanent Middle Cerebral Artery Occlusion". Brain Edema XI. Vol. 76. pp. 331–333. doi:10.1007/978-3-7091-6346-7_68. ISBN 978-3-7091-7257-5. ISSN 0065-1419. PMID 11450037.
{{cite book}}:|journal=ignored (help) - ^ Qiu, H.; Hedlund, L. W.; Gewalt, S. L.; Benveniste, H.; Bare, T. M.; Johnson, G. A. (1997). "Progression of a focal ischemic lesion in rat brain during treatment with a novel glycine/NMDA antagonist: an in vivo three-dimensional diffusion-weighted MR microscopy study". Journal of Magnetic Resonance Imaging. 7 (4): 739–744. doi:10.1002/jmri.1880070421. ISSN 1053-1807. PMID 9243396.